Adjunctive Brexpiprazole 1 and 3 mg for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants
Michael E. Thase(Veterans Health Administration), Hans Eriksson(HolsboerMaschmeyer NeuroChemie (Germany)), Margaretta Nyilas, William H. Carson(University of Chicago), Raymond Sanchez, James M. Youakim(Acadia Pharmaceuticals (United States)), Robert D. McQuade, Peter Zhang(Acadia Pharmaceuticals (United States)), Mary Hobart(Otsuka (United States)), Aleksandar Skuban
Cited by 164
Related Papers
The 16-Item quick inventory of depressive symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression
|Biological Psychiatry|2003|3.9k
A Comparison of Nefazodone, the Cognitive Behavioral-Analysis System of Psychotherapy, and Their Combination for the Treatment of Chronic Depression
|New England Journal of Medicine|2000|1.3k
Sequenced treatment alternatives to relieve depression (STAR*D): rationale and design
|Controlled Clinical Trials|2004|1.1k
Frontiers of cognitive therapy
|General Hospital Psychiatry|1997|1.1k